Product Images Desvenlafaxine
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 7 images provide visual information about the product associated with Desvenlafaxine NDC 68788-7194 by Preferred Pharmaceutical, Inc., such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Desvenlafaxine Extended Release Tablets 50mg
CAUTION: Federal law prohibits transfer of Desvenlafaxine Extended-Release Tablets 50mg to anyone other than the person for whom it was prescribed. Desvenlafaxine is an antidepressant medication used to treat major depressive disorder. This pill contains desvenlafaxine succinate and other ingredients, amounting to 50mg of the medication. The manufacturer of the medication is Breckenridge Pharmaceuticals, Inc. It is important to note the expiration date and lot number for proper usage. This information is useful for anyone who is prescribed Desvenlafaxine Extended-Release Tablets 50mg.*
Figure 1 - desvenlafaxine figure1
This appears to be a report on the effects of renal and hepatic impairment on the pharmacokinetics (PK) of some substance(s). The report shows the geometric mean ratios (and their confidence intervals) for Cmax and AUC (two important pharmacokinetic parameters) for different levels of impairment compared to normal (reference). The report also includes data on the effects of gender and age on PK.*
Figure 2 - desvenlafaxine figure2
This text appears to be a statistical analysis of the change in Cmax and AUC levels for Ketoconazole, a CYP3A4 inhibitor, with respect to a reference. The increase in Cmax is 1.08 and the increase in AUC is 1.43. These values are represented as geometric mean ratios with a 30% confidence level. No further information or context is provided.*
Figure 3 - desvenlafaxine figure3
Figure 4 - desvenlafaxine image4
This appears to be a graph displaying the estimated proportion of patients with relapse over time, with the x-axis showing the time to relapse in days from randomization and the y-axis showing the proportion of patients with relapse. The graph compares the relapse rates between Desvenlafarine Extended-Release Tablets (at a dose of 50mg) and Placebo. At the 10-day mark, the estimated proportion of patients with relapse is 10%. Beyond that, it is unclear what specific values or percentages are being represented by the graph.*
Figure 5 - desvenlafaxine image5
This is a graph showing the estimated proportion of patients with relapse over time (in days) from randomization. The graph compares Desvenlafaxine Extended-Release Tablets to Placebo, with percentages ranging from 20% to 50%. The x-axis denotes time and the y-axis term shows the estimated proportion of patients experiencing a relapse.*
Structure - desvenlafaxine structure1
This is not-available as the text is incomplete and doesn't provide enough context.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.